Latest Racing News

Syntara Limited has reported positive final data from its Phase 2a trial of amsulostat in myelofibrosis, demonstrating significant symptom relief and spleen volume reduction with a favorable safety profile. These results pave the way for advancing clinical development and partnership discussions.

Tungsten Mining NL has successfully raised $9.5 million through a share placement to advance its Mt Mulgine gold-tungsten project, reinforcing its position in the global tungsten market.

Firebird Metals has raised A$6 million through a placement led by top-tier institutions and directors, aiming to fast-track its manganese-rich cathode technology and expand R&D capabilities in Australia and China.

Redcastle Resources and BML advance their strategic gold joint venture with key studies completed and mining proposal submission expected by late 2025, targeting initial production in early 2026.

Hastings Technology Metals has signed a binding agreement to sell its gold assets to Metal Bank Limited in a share-and-cash deal, marking a strategic pivot towards rare earths and niobium development.

INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.

Great Boulder Resources has raised $5 million through a strategic placement led by Tribeca Investment Partners, positioning the company to accelerate exploration and target a one million ounce gold resource at its Side Well project.

Kula Gold has reported a significant high-grade niobium soil anomaly exceeding 1% Nb2O5 over a 1.5km strike at its Wozi Project in Malawi, with maiden drilling planned for November 2025. This discovery positions the company strategically within the critical minerals sector alongside its gold exploration efforts.

Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.

HeraMED is fast-tracking its AI-driven maternity care technologies, including an early release of its AI Clinician Assistant and predictive models for high-risk pregnancies, aiming to revolutionize digital women’s health globally.

X2M Connect has secured a significant contract to digitise water meters for 6,750 Seoul households, marking a key step in the city's ambitious A$240 million smart metering initiative.

CloudHolter Pty Ltd reported a substantial $39.7 million net loss for FY2025 amid ongoing cash outflows but continues to raise capital through convertible notes as it targets an IPO by year-end.